ExpreS2ion Biotechnologies – Presentation of Q1 2023

Af HC Andersen Capital

ExpreS2ion Biotechnologies is expected to release its Q1 2023 results on 16 May 2023. Later the same day at 11:00, ExpreS2ion Biotechnologies’ CEO Bent Frandsen and CFO Keith Alexander will present the results and latest achievements followed by a Q&A session in a virtual live event.

Besides the quarterly results, we expect attention, among others, could be directed to the outcome of the rights issue, the development in the pipeline, and the poster on ES2B-C001, the HER2-VLP breast cancer vaccine candidate, which was presented at the AACR Annual Meeting.

ExpreS2ion Biotechnologies is a Danish biotechnology company, which focuses on the development of vaccines for diseases such as COVID-19, influenza, and breast cancer through the use of its non-viral Drosophila S2 cells-based expression system.

HC Andersen Capital receives payment from ExpreS2ion Biotechnologies for a Corporate Visibility/Digital IR subscription agreement. /Michael Friis 13.30 PM 28-04-2023.